Inhibition of MST3, a STE20-type kinase, alleviates metabolic dysfunction-related steatohepatitis in mice without influencing the development of hepatocellular carcinoma - Report - MDSpire
Advertisement
Inhibition of MST3, a STE20-type kinase, alleviates metabolic dysfunction-related steatohepatitis in mice without influencing the development of hepatocellular carcinoma
Inhibition of MST3 Alleviates Metabolic Dysfunction-Related Steatohepatitis
Overview
Revise to include specific data supporting the relationship between MST3 inhibition and HCC risk.
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern, affecting over 30% of the population and leading to conditions such as MASH and hepatocellular carcinoma (HCC). The increasing prevalence of MASLD highlights the need for effective treatments, especially as MASH has emerged as a significant contributor to HCC development. Understanding the molecular mechanisms involved in MASLD progression is crucial for developing targeted therapies.
Data Highlights
No numerical data presented in the article.
Key Findings
MST3, MST4, and STK25 are key drivers of hepatocellular steatotoxicity and correlate with MASH severity.
Inhibition of MST3 in mice improved metabolic profiles and reduced MASH severity without affecting HCC tumor burden.
Silencing of MST3, MST4, or STK25 in human hepatocytes reduces ectopic fat deposition and enhances resistance to lipotoxicity.
In vivo studies showed that MST3 inhibition protects against diet-induced MASH features.
Gene expression of MST3, MST4, and STK25 is elevated in human HCC tissues compared to non-tumor controls.
Clinical Implications
The findings suggest that targeting MST3 may provide a therapeutic avenue for alleviating MASH without increasing the risk of HCC. Clinicians should consider the role of GCKIII kinases in managing patients with metabolic liver diseases, particularly in those at risk for progression to HCC.
Conclusion
Inhibition of MST3 presents a promising strategy for managing MASH while maintaining a neutral impact on HCC development, warranting further investigation in clinical settings.
by Jingjing Zhang, Xiangdong Gongye, Lohitesh Kovooru, Emma Andersson, Bernice Asiedu, Manoj Amrutkar, Nadia Gul, Caitlyn Myers, Sheri Booten, Dan Emil Lind, Ying Xia, Antonio Molinaro, Anetta Härtlova, Per Lindahl, Sue Murray, Margit Mahlapuu
